Featured Outsourcing Editorial
-
Building Quality Into Radiopharmaceuticals: A Look At EMA's Recent Guideline
4/28/2026
The EMA's December 2025 draft guideline on expectations for the quality documentation of radiopharmaceuticals replaces the earlier 2007 guideline and reflects significant developments.
-
Overcoming 3 Key Challenges Of Working With CDMOs For Radiopharmaceuticals
4/27/2026
Radiopharmaceuticals have a level of operational complexity that challenges traditional outsourcing models. Address these three critical challenges early and intentionally.
-
Selecting The Right eQMS To Maximize Quality Maturity
4/23/2026
Let's take a closer look at the current electronic quality management system (eQMS) landscape in pharma/biotech and what a future-ready eQMS must enable to support continuous improvement.
-
How AI Could Clear Logistics Roadblocks Limiting Patient Access To CGT
4/23/2026
Patient access often gets mischaracterized solely as a cost and pricing issue. A discussion among industry leaders reaches a deeper, more complex conclusion.
-
FDA's First cGMP Enforcement Action On AI Misuse In Drug Manufacturing
4/22/2026
The warning letter, issued to Purolea Cosmetics Lab, describes a manufacturer that used AI agents to generate drug product specifications and more. Here's why the outsourced pharma industry should take note.
-
Validating Candel's BLA-Ready Analytics Profile
4/22/2026
The adenovirus/prodrug company discusses in-house assay development and the validation work to confirm CQAs like potency and cell line integrity.
-
Mapping Candel Therapeutics' Sprint To The BLA Finish Line
4/22/2026
Leaders from the adenovirus/prodrug developer discuss the complex balancing act of preparing to scale up for commercial manufacturing without overextension.
-
The Hidden Operational Cost Contained In Every Small Molecule Portfolio
4/21/2026
The volume of post-approval changes is rising and the manual approaches that have worked until now are no longer adequate. Get ahead of this to spend less and execute faster.
-
Field Notes: APEC RHSC's Workshop On ATMP Development And Evaluation
4/15/2026
Scientific and regulatory leaders in the Asia-Pacific region met recently for an exchange of strategies to strengthen convergence and technical competence.
-
U.S. Pharma Tariffs And MFN Become Law After April 2 Update
4/15/2026
Beginning July 31, 2026, a U.S. pharmaceutical tariff will apply to patented products and their APIs, beginning with large companies. Beroe Inc.'s Mathini Ilancheran breaks down the tariff's impact, explores its risks, and proposes five procurement strategies to addressing them.